TG1050

Home/TG1050

Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

Poster 0710-AASLD 2019-TG1050-T101_Metaanalyse Fabien Zoulim et al. AASLD 2019 Download [...]

By |2020-03-22T17:47:45+01:00November 8th, 2019|Publication, TG1050|Comments Off on Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China

TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.

Perrine Martin, et al. Hepatology, 2013, (58) S1, 222A–225A – [...]

By |2019-07-03T14:56:47+02:00October 15th, 2013|Publication, TG1050|Comments Off on TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.
Go to Top